Table 5. Baseline characteristics in relation to clinical meaningful changes in composite Visual Function Questionnaire scores at 3 and 12 months.
| 3 months follow-up | 12 months follow-up | |||||||
| Increase (n = 62) | No change (n = 86) | Decrease (n = 39) | P-value | Increase (n = 41) | No change (n = 81) | Decrease (n = 49) | P-value | |
| Age, median (IQR), years | 77 (73–82) | 79 (75–85) | 80 (76–84) | 0.22a | 78 (74–82) | 78 (74–83) | 79 (75–84) | 0.43a |
| Sex (male), n (%) | 20 (32) | 24 (28) | 14 (36) | 0.65b | 13 (32) | 22 (27) | 15 (31) | 0.85b |
| Composite VFQ score | 72 (57–82) | 89 (81–93) | 83 (60–91) | <0.001a | 69 (53–80) | 89 (79–93) | 86 (69–90) | <0.001a |
| BCVA of the better eye, ETDRS letters | 74 (56–81) | 78 (70–85) | 71 (63–78) | 0.03a | 76 (54–80) | 78 (71–85) | 71 (64–78) | 0.005a |
| BCVA of the worse eye, ETDRS letters | 48 (22–66) | 50 (31–67) | 48 (29–57) | 0.48a | 50 (22–67) | 55 (41–68) | 46 (26–60) | 0.05a |
| Foveal morphology in the better eye | ||||||||
| CFT, n (%) | ||||||||
| <170 µm | 7 (11) | 2 (2) | 1 (3) | 6 (15) | 1 (1) | 2 (4) | ||
| ≥170 µm and <270 µm | 27 (44) | 47 (55) | 16 (41) | 0.10c | 20 (49) | 48 (59) | 18 (37) | 0.004c |
| ≥270 µm | 28 (45) | 37 (43) | 22 (56) | 15 (37) | 32 (40) | 29 (59) | ||
| CFN, n (%) | ||||||||
| <170 µm | 8 (13) | 4 (5) | 4 (10) | 7 (17) | 3 (4) | 4 (8) | ||
| ≥170 µm and <270 µm | 38 (61) | 59 (69) | 21 (54) | 0.26c | 24 (59) | 59 (73) | 29 (59) | 0.09c |
| ≥270 µm | 16 (26) | 23 (27) | 14 (36) | 10 (24) | 19 (23) | 16 (33) | ||
| RPE elevation, n (%) | ||||||||
| Not present | 39 (63) | 54 (63) | 21 (54) | 0.59b | 26 (63) | 50 (62) | 27 (55) | 0.68b |
| Present | 23 (37) | 32 (37) | 18 (46) | 15 (37) | 31 (38) | 22 (45) | ||
| IS/OS status, n (%) | ||||||||
| Complete | 20 (32) | 48 (56) | 9 (23) | 16 (39) | 43 (53) | 13 (27) | ||
| Interrupted | 16 (26) | 15 (17) | 8 (21) | 0.002b | 8 (20) | 17 (21) | 12 (24) | 0.03b |
| Absent | 26 (42) | 23 (27) | 22 (56) | 17 (41) | 21 (26) | 24 (49) | ||
| ELM status, n (%) | ||||||||
| Complete | 25 (40) | 51 (59) | 12 (31) | 18 (44) | 46 (57) | 19 (39) | ||
| Interrupted | 15 (24) | 20 (23) | 9 (23) | 0.03b | 9 (22) | 16 (20) | 11 (22) | 0.29b |
| Absent | 22 (35) | 38 (44) | 18 (46) | 14 (34) | 19 (23) | 19 (39) | ||
Abbreviations used: IQR = interquartile range, VFQ = Visual Function Questionnaire, BCVA = best-corrected visual acuity, ETDRS = Early Treatment Diabetic Retinopathy Study, CFT = total central foveal thickness, CFN = central foveal thickness of the neuroretina, RPE = retinal pigment epithelium, IS/OS = inner segment/outer segment junction, ELM = external limiting membrane.
a
Kruskal-Wallis test.
b
Chi-square test.
c
Fischer's Exact Test.